RG
PACB icon

Redmile Group’s Pacific Biosciences PACB Stock Holding History

Redmile Group’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-237,977
Closed -$1.87M – 62
2014
Q4 		$1.87M Buy
+237,977
New +$1.52M 0.2% 44
2013
Q4 		– Sell
-1,574,379
Closed -$8.71M – 61
2013
Q3 		$8.71M Sell
1,574,379
-876,201
-36% -$3.04M 1.31% 29
2013
Q2 		$6.2M Buy
+2,450,580
New +$6.1M 1.09% 34

Other funds holding PACB

MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Redmile Group's PACB Position: Q1 2015 in Review

Redmile Group sold out of Pacific Biosciences (PACB) in Q1 2015, closing a stake of 237,977 shares — an estimated $1.87M sold.

Redmile Group first reported a position in PACB in Q2 2013 and held it in 3 quarters. The position peaked at $8.71M in Q3 2013. 94 funds tracked by Wall St. Rank hold PACB as of Q1 2015.

  • Redmile Group reported no remaining Pacific Biosciences position as of Q1 2015 after selling out during the quarter.
  • Redmile Group sold 237,977 Pacific Biosciences shares in Q1 2015, an estimated $1.87M.
  • Redmile Group first reported a position in Pacific Biosciences in Q2 2013 and held it in 3 quarters.
  • Redmile Group's Pacific Biosciences position peaked at $8.71M in Q3 2013.
  • 94 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2015.

Based on Redmile Group's 13F filing for Q1 2015, filed 18 May 2015.